CBIO-28. IDENTIFYING THE ROLE OF MISMATCH REPAIR IN TEMOZOLOMIDE-INDUCED ATR ACTIVATION FOR MGMT-METHYLATED GLIOBLASTOMA MULTIFORME. (12th November 2021)

• Record Type: Journal Article
• Authors: Ganesa, Sachita; Sule, Amrita; Sundaram, Ranjini; Bindra, Ranjit
• Is Part Of: Neuro-oncology. Volume 23: Supplement 6(2021)
• Page Start: vi32
• Page End: vi33
• Publication Date: 2021-11-12
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noab196.126
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: The methylation status of the O 6 -methyl guanine methyltransferase (MGMT) gene promoter is a prognostic biomarker for treatment with the alkylator, temozolomide (TMZ) in many solid tumors including gliomas and colorectal cancers. It is well established that patients with a methylated MGMT promoter (MGMT - ) who are treated with the TMZ have a better overall survival than patients with an unmethylated MGMT promoter (MGMT + ). The enzyme produced by the MGMT gene is responsible for removing cytotoxic O 6 -methylguanine (O 6 -meG) lesions formed by TMZ. In the MGMT - setting, the O 6 -meG lesion activates the mismatch repair (MMR) pathway which functions to remove the damage. Published work from our group reported differential activation of the ataxia telangiectasia and RAD3 related protein (ATR) in MGMT - and MGMT + glioblastoma multiforme (GBM) cells in response to TMZ treatment, as demonstrated through the phosphorylation of CHK1. Though it is known that MMR proteins are involved in ATR activation, the specific MMR proteins required for ATR activation by TMZ-induced alkyl lesions remain unknown in the MGMT - setting. Here, we demonstrate that specific mismatch repair proteins, including MSH2, MSH6, and PMS2 play a role in ATR activation in the presence of O 6 -meG lesions. We show that there is potent synergy with ATRi and TMZ in the MGMT - MMR- proficient GBM cell line, which is abrogated in an shMMR MGMT - GBM cell line. Additionally, we observe decreased levels of pCHK1 in the shMMR MGMT - setting compared to the MGMT - MMR-proficient cells, suggesting that MMR is integral in the activation of ATR upon TMZ treatment. Mechanistic understanding of how the MMR system is involved in ATR activation by TMZ can ultimately be exploited for therapeutic gain.